Sign inJoin waitlistJoin the waitlist

Mark Litzow

Professor of Medicine · Mayo Clinic College of Medicine and Science

Credentials: · · ·

History

Mayo Clinic College of Medicine and Science
Present

Hematology and Medical Oncology
Mayo Clinic College of Medicine and Science
1985–1988
1983–1985
Internal Medicine
1980–1983
University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine
1976–1980

Research

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia
New England Journal of Medicine · 2012 · 1,623 citations
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
The Lancet Oncology · 2015 · 1,047 citations
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium
Biology of Blood and Marrow Transplantation · 2016 · 880 citations

William Hogan
219 papers
Ayalew Tefferi
161 papers
Aref Al-Kali
157 papers · 5 as a fellow
Mrinal Patnaik
149 papers
Hassan Alkhateeb
129 papers · 6 as a fellow
Naseema Gangat
123 papers
Kebede Begna
114 papers
Mithun Shah
108 papers
Hillard Lazarus
102 papers
MT
Martin Tallman
97 papers
James Foran
88 papers
Abhishek Mangaonkar
82 papers · 6 as a fellow

Grants

Dendritic Cell Therapy of Chronic Myelogenous Leukemia
National Cancer Institute · R01
Contact PI · $1M · Mayo Clinic Rochester
2001–2006

Clinical trials

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Principal investigator · Active not recruiting · Phase 3
National Cancer Institute (NCI)
2014–2027
Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD)
Principal investigator · Withdrawn
Mayo Clinic
2012–2017
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2008–2014
The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.
Principal investigator · Completed · Phase 3
Mayo Clinic
2001–2007